Salvation and Sin concludes with a reading of Julian of Norwich's profound, compassionate, and widely admired theology, a reading which brings her Showings into conversation both with Langland and Augustine. His thesis will revise the way in which this canonical text is read. In Langland's poem, Aers finds a theology and ethics shaped by Christology where the poem's modes of writing are intrinsic to its doctrine. From their work, Aers moves to his central text, William Langland's Piers Plowman, a long multigeneric poem contributing profoundly to late medieval conversations concerning theology and ecclesiology. After the opening chapter on Augustine, Aers turns to the exploration of these concerns in the work of two major theologians of fourteenth-century England, William of Ockham and Thomas Bradwardine. 1285, Ockham, Surrey, Eng.died 1347/49, Munich, Bavaria), English Franciscan philosopher, theologian, and political writer. Augustine becomes a major interlocutor in this book: his vocabulary and grammar of divine and human agency are central to Aers' exploration of later writers and their works. William of Ockham, or William of Occam, (born c. Theologies of grace and versions of Christian identity and community are its pervasive concerns. Salvation and Sin explores various modes of displaying the mysterious relations between divine and human agency, together with different accounts of sin and its consequences. Working at the nexus of theology and literature, he combines formidable theological learning with finely detailed and insightful close readings to explore a cluster of central issues in Christianity as addressed by Saint Augustine and by four fourteenth-century writers of exceptional power. Ockham also plans to use the acquisition to expand its FSP into clinical, which is Nexus’ specialty.In Salvation and Sin, David Aers continues his study of Christian theology in the later Middle Ages. “As a result, we’ve created this nice niche where, at the end of the day, we’ve become known as one of the top five early-stage oncology CROs.” “The small trials we work on require a certain amount of leadership, and the large guys can’t do that as efficiently as we do,” he said. Ockham and Nexus both compete with other small, oncology-focused CROs including Novella, Aptiv and Premier, said Baker. The company stayed with the market segment Ockham had been serving: emerging biotech and pharma companies seeking help with phase I and II trials. In 2009, said Baker, the company acquired five-year-old Ockham, a “distressed” full-service CRO with 60 employees. Over time, it began working with pharma companies, providing CRAs, data managers, statistical programmers and biostatisticians, and eventually offering functional service provider (FSP) services to companies working on cancer drugs. Ockham launched in 1986 as ASG, a specialty staffing company focusing primarily on IT. But Baker said by yearend Ockham will make a final decision on the combined entity’s name. For now, Nexus Oncology will be known as Nexus Oncology, an Ockham Company. Nexus founder Clare Wareing will stay as chief scientific officer. Ockham had 175 employees before the acquisition and operated primarily in the U.S., with satellite offices in India and the U.K. Twelve-year-old Nexus has 120 employees across Scotland, Poland, France, Germany, Sweden, Switzerland, Hungary, Belgium and Spain, in addition to Canada and the U.S.
James Baker, Ockham’s CEO, said Nexus comes with a stable book of business and an institutional investment partner. Ockham Development Group provides clinical development services for cancer projects. Terms of the cash-and-stock deal were undisclosed. Headquarters Regions Research Triangle, East Coast, Southern US. Ockham Development Group of Cary, N.C., has acquired Nexus Oncology of Edinburgh, Scotland. Two small but powerful oncology-focused CROs are now one.
0 kommentar(er)
